Announcement on Voluntary Disclosure of Obtaining FDA Approval for Clinical Trial Application for HP515 Tablets to Treat Metabolic Dysfunction-Associated Steatohepatitis (MASH)

About this update from Hinova Pharmaceuticals, Inc. Class A

Announcement on Voluntary Disclosure of Obtaining FDA Approval for Clinical Trial Application for HP515 Tablets to Treat Metabolic Dysfunction-Associated Steatohepatitis (MASH)The abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hinova Pharmaceuticals, Inc. Class A